ArticleOncotarget2015

SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3.

Filipa Quintela Vieira et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.